Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting

Small molecular fluorescent probes featuring protein-assisted functional amplification for improved biosensing and cancer therapeutics

In recent years, small molecular fluorescent probes have significantly advanced biosensing and cancer therapy, enabling applications such as target detection, cellular imaging, fluorescence-guided surgery, and phototherapy. However, conventional small molecular probes face limitations, including low biocompatibility, poor stability, and weak signal intensity. Protein-coordinated fluorescent probes have emerged as a promising solution, leveraging protein-assisted functional amplification to address these challenges. Mechanisms such as environmental shielding, conformational restriction, charge stabilization, and increased local concentration collectively enhance fluorescence emission and phototherapeutic efficacy. This article reviews recent progress (primarily within the last five years) in protein-coordinated fluorescent probes for biosensing and cancer therapy. It begins with a systematic summary of the interaction strategies between proteins and fluorescent probes and details key mechanisms behind protein-assisted functional amplification. Subsequently, the applications of these probes in biosensing and cancer therapy are comprehensively concluded. Finally, current challenges and future prospects are discussed in depth. This review aims to refine design strategies for protein-coordinated fluorescent probes and inspire innovative approaches in biosensing and cancer therapy.

Modulation of photoacoustic NIR BODIPY self-assembly in theranostic solid lipid nanoparticles via alpha-group variation: influence on spectral and nanostructural properties

Loading drug nanovectors with a high quantity of near-infrared organic dye considerably increases their absorption cross-section and favors their detection as theranostic agents with photoacoustic imaging. In a previous study, solid lipid nanoparticles (SLNs) of dexamethasone palmitate were labeled with BODIPY-aniline-palmitate and revealed exquisite photoacoustic properties: a NIR absorption cross-section comparable to gold nanoparticles and a photoacoustic generation efficiency above 1. However, strong and gradual spectral modifications were observed with the increasing dye concentration. The spectral transformations were linked to dye aggregation in the SLNs, and potential further transformations occuring after in vivo injection may hinder longitudinal imaging applications. In the present study, we introduce BODIPY-julolidine-palmitate, a second dye able to label the SLNs, but without any marked aggregation behaviour. We perform a comparative study of labelled SLNs in various matching concentrations of each dye in terms of optical and photoacoustic properties, showing lower modifications of the spectral behaviour with the dye concentration for BODIPY-judolidine and establishing the influence of the lipid core on the photoacoustic generation efficiency regardless of the dye. Cryo-EM and SAXS-WAXS studies reveal a lamellar arrangement at the nanoscale for SLNs labelled with a high concentration of BODIPY-aniline whereas SLNs labelled with BODIPY-julolidine display an amorphous structure. Overall, BODIPY-julolidine-palmitate at moderate label concentration appears a better candidate to label SLNs for theranostic applications using photoacoustic imaging.

Activatable Molecular Probes With Clinical Promise for NIR-II Fluorescent Imaging

The second near-infrared window (NIR-II) fluorescence imaging has been widely adopted in basic scientific research and preclinical applications due to its exceptional spatiotemporal resolution and deep tissue penetration. Among the various fluorescent agents, organic small-molecule fluorophores are considered the most promising candidates for clinical translation, owing to their well-defined chemical structures, tunable optical properties, and excellent biocompatibility. However, many currently available NIR-II fluorophores exhibit an "always-on" fluorescence signal, which leads to background noise and compromises diagnostic accuracy during disease detection. Developing NIR-II activatable organic small-molecule fluorescent probes (AOSFPs) for accurately reporting pathological changes is key to advancing NIR-II fluorescence imaging toward clinical application. This review summarizes the rational design strategies for NIR-II AOSFPs based on four core structures (cyanine, hemicyanine, xanthene, and BODIPY). These NIR-II AOSFPs hold substantial potential for clinical translation. Furthermore, the recent advances in NIR-II AOSFPs for NIR-II bioimaging are comprehensively reviewed, offering clear guidance and direction for their further development. Finally, the prospective efforts to advance NIR-II AOSFPs for clinical applications are outlined.

WazaGaY: An Innovative Aza-BODIPY-Derived Near-Infrared Fluorescent Probe for Enhanced Tumor Imaging

Aza-BODIPYs represent a class of fluorophores in which the π-conjugated system is rigidified and stabilized by a boron atom. A promising strategy to enhance their fluorescence properties involves replacing the boron atom with a metal ion. Here, we describe the synthesis and characterization of a water-soluble derivative where the metal is a gallium(III) ion, termed WazaGaY (water-soluble aza-GaDIPY). Water solubility is ensured by two ammonium substituents, inducing a bathochromic shift and a significant increase in quantum yield compared to that of the dimethylamino analog. The cellular behavior of WazaGaY-1 was observed across different tumor cells. In vivo, the distribution and safety profiles were determined, and tumor uptake was assessed in various tumor types. Following intravenous injection, WazaGaY-1 enabled clear discrimination of tumors engrafted subcutaneously in mice with high tumor-to-muscle ratios (ranging from 7 to 20), even in the absence of specific conjugation. Its potential as a contrast agent for fluorescence-guided surgery was confirmed.

Comparison of the In Vitro and In Vivo Behavior of a Series of NIR-II-Emitting Aza-BODIPYs Containing Different Water-Solubilizing Groups and Their Trastuzumab Antibody Conjugates

The development of new fluorescent organic probes effective in the NIR-II region is currently a fast-growing field and represents a challenge in the domain of medical imaging. In this study, we have designed and synthesized an innovative series of aza-boron dipyrromethenes emitting in the NIR-II region. We have investigated the effect of different water-solubilizing groups not only on the photophysical properties of the compounds but also on their in vitro and in vivo performance after bioconjugation to the antibody trastuzumab. Remarkably, we discovered that the most lipophilic compound unexpectedly displayed the most favorable in vivo properties after bioconjugation. This underlines the profound influence that the fluorophore functionalization approach can have on the efficiency of the resulting imaging agent.

NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer

Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA-approved anti-HER2 antibody, namely, trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum and a maintained affinity toward HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo and thus their potential for NIR-II FGS in the cancer setting.

Low-density lipoprotein: a versatile nanoscale platform for targeted delivery

Low-density lipoprotein (LDL) is a small lipoprotein that plays a vital role in controlling lipid metabolism. LDL has a delicate nanostructure with unique physicochemical properties: superior payload capacity, long residence time in circulation, excellent biocompatibility, smaller size, and natural targeting. In recent decades, the superiority and feasibility of LDL particles as targeted delivery carriers have attracted much attention. In this review, we introduce the structure, composition, advantages, defects, and reconstruction of LDL delivery systems, summarize their research status and progress in targeted diagnosis and therapy, and finally look forward to the clinical application of LDL as an effective delivery vehicle.

Recent advances in NIR-II fluorescence based theranostic approaches for glioma

Gliomas are among the most common malignant tumors in the central nervous system and lead to poor life expectancy. However, the effective treatment of gliomas remains a considerable challenge. The recent development of near infrared (NIR) II (1000-1700 nm) theranostic agents has led to powerful strategies in diagnosis, targeted delivery of drugs, and accurate therapy. Because of the high capacity of NIR-II light in deep tissue penetration, improved spatiotemporal resolution can be achieved to facilitate the in vivo detection of gliomas via fluorescence imaging, and high contrast fluorescence imaging guided surgery can be realized. In addition to the precise imaging of tumors, drug delivery nano-platforms with NIR-II agents also allow the delivery process to be monitored in real-time. In addition, the combination of targeted drug delivery, photodynamic therapy, and photothermal therapy in the NIR region significantly improves the therapeutic effect against gliomas. Thus, this mini-review summarizes the recent developments in NIR-II fluorescence-based theranostic agents for glioma treatment.